Stockreport

PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch

Nuvectis Pharma, Inc.  (NVCT) 
PDF With its focus on targeting well-defined subgroups by inhibiting SRC/YES1 kinases in Non Small-Cell Lung Cancer patients resistant to EGFR and ALK targeted therapies, Nu [Read more]